{"id":"W4391792531","doi":"10.1016/j.jtocrr.2024.100645","title":"Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib","year":2024,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"National Cancer Institute; National Institutes of Health; Array BioPharma; Massachusetts General Hospital; Lunit; Amgen; Pfizer; Agios Pharmaceuticals; Bristol-Myers Squibb","keywords":"Alectinib; Medicine; Oncology; Crizotinib; Internal medicine; Lung cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001072212,0.0003502985,0.0008124522,0.0001830511,0.0001747652,0.0004725086,0.0003367669,0.0003143369,0.0004193508],"category_scores_gemma":[0.001483725,0.0001401025,0.0007057643,0.0002866851,0.0002514048,0.0002943888,0.0002388093,0.0008264821,0.0001491016],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006939919,"about_ca_system_score_gemma":0.0005587456,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004877172,"about_ca_topic_score_gemma":0.001016714,"domain_scores_codex":[0.9996471,0.0001160874,0.0000433357,0.00007089856,0.00007336325,0.00004908369],"domain_scores_gemma":[0.9993123,0.0001471492,0.0002659039,0.00006182436,0.00004545766,0.0001673456],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1946189,0.006998843,0.5039476,0.000538677,0.002812039,0.001540098,0.0005500433,0.008217649,0.04719354,0.0001613718,0.001786262,0.231635],"study_design_scores_gemma":[0.02232321,0.1272421,0.8276775,0.0001024886,0.001405672,0.003653037,0.0001618884,0.007418467,0.007293776,0.0002019248,0.002466318,0.00005358911],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9991056,0.0005245803,0.00005925915,0.00004930366,0.000004750446,0.00002416696,0.0000576161,0.000005723321,0.0001690633],"genre_scores_gemma":[0.999488,0.0001534112,0.00008605694,0.00004442617,0.000009467053,0.00001650657,0.0001480244,0.000001114366,0.00005298893],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001072212,"threshold_uncertainty_score":0.005670488,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03893543307576351,"score_gpt":0.4216651979989756,"score_spread":0.382729764923212,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}